# OnCo record paper-nct05840016-lancet-2025 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-nct05840016-lancet-2025/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-nct05840016-lancet-2025" ;
  schema:name "Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial"@en ;
  schema:description "Published report from the trial registered as NCT05840016, in The Lancet (2025), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-nct05840016-lancet-2025/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s0140-6736(25)01848-3>, <https://pubmed.ncbi.nlm.nih.gov/41125109/>, <https://europepmc.org/article/MED/41125109>, <https://clinicaltrials.gov/study/NCT05840016> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s0140-6736(25)01848-3> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "Chen Z, Yang F, Jiang Z, et al." ;
  onco:trials <https://onco.cc/trials/nct05840016/> ;
  onco:journals <https://onco.cc/journals/lancet/> .